Microvention, a wholly owned subsidiary of Terumo Corp., recently completed its first STRAIT study enrollment of its BOBBY Balloon Guide Catheter. “The STRAIT trial aims to provide clinical evidence that Microvention’s new balloon guiding catheter can effectively help improve clinical outcomes,” said the company’s President and CEO, Carsten Schroeder.
BOBBY is designed to streamline balloon preparation while improving airworthiness and providing compatibility with the company’s SOFIA Plus 6Fr Aspiration Catheter. It is currently approved in Europe and North America. The device is intended for use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel in the peripheral and neurovascular systems. The balloon provides temporary vascular occlusion during these and other angiographic procedures. It is also suitable for use as a conduit for recovery devices.
The first patient in the STRAIT study was recruited from the site by PD Principal Investigator med Dr. Tobias Boeckh-Behrens, Department of Diagnostic and Interventional Neuroradiology.
“A severe stroke case with left carotid occlusion was successfully treated with the use of BOBBY resulting in a first pass TICI 3, 20 minutes after the groin procedure,” commented Dr Christian Maegerlein, who treated the patient with BOBBY. “We were pleased with the excellent performance of the BOBBY BGC with the SOFIA Plus 6Fr Aspiration Catheter, Headway Microcatheter, Traxcess EX Guidewire and 6 x 40 Stent Retrieval Revascularization Device.”